Eli Lilly’s weight loss and diabetes drug tops Keytruda
Digest more
By Mrinalika Roy and Bhanvi Satija (Reuters) -As obesity drug heavyweights Eli Lilly and Novo Nordisk gear up to release ...
U.S. sales of Lilly’s weight-loss treatment Zepbound nearly tripled, to $3.57 billion, in the third quarter. Meanwhile, ...
Eli Lilly & Co. failed to prove in a federal court that a business selling copycat versions of its obesity drug causes harm ...
Eli Lilly and Co. is funding and participating in an Indiana University study that examines the health outcomes of people on ...
Tirzepatide, which Lilly sells as Mounjaro for diabetes and Zepbound for obesity, topped $10 billion in the third-quarter, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback